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To the Editor,
We would like to respond to the letter from Wen-Ling
Lee, Hsiang-Tai Chao and Peng-Hui Wang. First, thank
you for your important comments on our paper.
Second, you mention that recent randomized clin-
ical trials of postmenopausal hormone therapy (HT)
have informed clinical decision-making, but several
key questions remain unanswered. Observation stud-
ies suggest that HT prevents coronary heart disease
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(CHD), whereas randomized clinical trial has not con-
firmed a cardioprotective effect. A major difference
between participants in observational studies and those
in clinical trials is timing of initiation of HT in relation
to menopause onset. Women taking postmenopausal
hormones in observational studies typically start ther-
apy in early postmenopause, whereas clinical trial par-
ticipants are often randomly assigned to hormones
long after menses have ceased. In the United States,
the average age at menopause is 51 years. The 20-year
Nurses’ Health Study (NHS) is 1 of the largest prospec-
tive investigations of HT and CHD incidence. The
baseline ages of NHS participants ranged from 30 to
55 years, and approximately 80% of cohort members
who opted to use HT did so within 2 years of meno-
pause. Among 70,533 postmenopausal participants,
current use of HT was associated with a relative risk
of a major coronary event of 0.61 (95% confidence
interval, 0.52–0.71). In contrast, the mean baseline
ages of the Women’s Health Initiative (WHI) study
and the Heart and Estrogen/progestin Replacement
Study (HERS) were 63 and 67 years, respectively; the
majority of these women had been postmenopausal
for more than a decade at the time of enrolment.
Administration of exogenous hormones immediately
after oophorectomy, during the early stages of athero-
sclerosis, reduced the extent of plaque by 50%.1 Most
atherosclerosis progression (imaging) trials in humans
have been conducted among women with significant
coronary lesions at baseline and have not shown estro-
gen to be effective in slowing the rate of arterial narrow-
ing.2,3 However, 1 study of younger postmenopausal
women (50–59 years old) showed that the calcified
plaque burden in the coronary arteries was lower in
women assigned to estrogen than in those assigned to
placebo.4 The Estrogen in the Prevention of Athero-
sclerosis Trial (EPAT), which did not require partici-
pants to have significant lesions at entry, found that
micronized 17β-estradiol did retard the progression
of carotid atherosclerosis.5 Subgroup analysis of WHI
data also revealed that women who had initiated hor-
mone therapy closer to menopause tended to have re-
duced CHD risk compared with the increase in CHD
risk among women more distant from menopause.6
Transdermal estrogen may be less thrombogenic
than oral estrogen. The data from recent case-control
studies in France and the Estrogen and Thromboem-
bolism Risk (ESTHER) study showed that transdermal
estrogen was not associated with venous thromboem-
bolism. There is now a critical mass of data to support
the hypothesis that time since menopause and route
of estrogen administration may importantly influence
the benefit–risk ratio associated with HT. Thus, a 5-year
randomized trial (the Kronos Early Estrogen Prevention
Study) will evaluate the effectiveness of low-dose oral
estrogen and transdermal estradiol in preventing pro-
gression of atherosclerosis in recently postmenopausal
women.
Third, we used estriol 2 mg/day as the control
group to prevent a high dropout rate in the HT
study. According to our experience, if we use placebo
control for early postmenopausal women, the
dropout rate would be about 40–50%.
Fourth, effective low dose is the current trend for
HT. Current evidence from controlled trials indicates
that low-dose HT appears effective and safe. This
makes it a good choice for the alleviation of climac-
teric symptoms, and for this purpose, long-term
administration of low-dose HT does not seem to
impose serious health risks.7,8 Thus, we suggest estra-
diol gel of 1.25 g/day.
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